This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content

An Interview With Richard Pazdur, MD

JOP: What has your office accomplished in the year since it was established?

RP: We've continued many projects initiated earlier. These include workshops conducted with ASCO, the AACR [American Association for Cancer Research] and the ASH [American Society of Hematology] examining end points used in regulatory trials. These workshops examine end points that can potentially be used for drug approvals. In addition, a workshop goal is to identify areas where further clinical development is needed for validation of future end points. In the past, the FDA has conducted workshops on lung, prostate, and colorectal cancers. This year, we had workshops . . . [Click for More]